University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.
University of Kansas Health System, 4000 Cambridge Street, Kansas City, KS, 66103, USA.
J Hematol Oncol. 2022 May 21;15(1):67. doi: 10.1186/s13045-022-01290-8.
Although messenger RNA (mRNA) vaccines have established efficacy for prevention of severe SARS-CoV2 infection in the general population, their effectiveness in patients with malignancy, especially those on anti-neoplastic therapies, remains an area of open research. In order to better understand the risk of developing breakthrough SARS-CoV-2 infection and the outcomes associated with breakthrough infection for cancer patients, individual patient data from a curated outcomes database at the University of Kansas were retrospectively reviewed to determine the rate of breakthrough infection during an 8-month period encompassing the height of the delta variant surge. Although the rate of breakthrough infection in cancer patients after two doses of an mRNA vaccine remained low at 1.1%, hospitalization and death rates were 27 and 5%, respectively. Patients with hematologic malignancies, especially multiple myeloma, and those on anti-neoplastic therapy at the time of vaccination were found to be at higher risk for developing breakthrough infection.
尽管信使 RNA（mRNA）疫苗已被证明可有效预防普通人群中严重的 SARS-CoV-2 感染，但它们在恶性肿瘤患者中的有效性，特别是在接受抗肿瘤治疗的患者中的有效性，仍是一个有待研究的领域。为了更好地了解癌症患者发生突破性 SARS-CoV-2 感染的风险以及与突破性感染相关的结果，我们回顾性地分析了堪萨斯大学一个经精心整理的结局数据库中的个体患者数据，以确定在涵盖德尔塔变异株激增高峰期的 8 个月期间内突破性感染的发生率。尽管在接受两剂 mRNA 疫苗后，癌症患者的突破性感染发生率仍较低（1.1%），但住院率和死亡率分别为 27%和 5%。患有血液系统恶性肿瘤（尤其是多发性骨髓瘤）的患者以及在接种疫苗时接受抗肿瘤治疗的患者，发现其发生突破性感染的风险更高。
